about
JARID1B is a luminal lineage-driving oncogene in breast cancerCopynumber: Efficient algorithms for single- and multi-track copy number segmentation.Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancerThe breast cancer genome--a key for better oncologyIschemia caused by time to freezing induces systematic microRNA and mRNA responses in cancer tissue.Integrative functional genomics analysis of sustained polyploidy phenotypes in breast cancer cells identifies an oncogenic profile for GINS2Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control studyImproving breast cancer survival analysis through competition-based multidimensional modeling.A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancerSystematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status.Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancerTumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF.Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53.The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast CancerCopy number variations alter methylation and parallel IGF2 overexpression in adrenal tumors.The 5p12 breast cancer susceptibility locus affects MRPS30 expression in estrogen-receptor positive tumors.Genomic architecture characterizes tumor progression paths and fate in breast cancer patients.Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome.Triple-negative breast cancer and the need for new therapeutic targets.The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells.Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity.TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.Analyzing cancer samples with SNP arrays.The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer.
P50
Q24299326-446074CC-7FB2-4E42-9415-85AC29D349C3Q30536665-AC0A7FF6-6309-491B-B9B6-78AFD27C01B6Q30566197-C520BD73-B86E-4C50-8686-12264EC6BDB9Q34086632-8A17679F-608F-44A8-9E06-98C0A2B1D9A1Q34216309-0A90BC30-A620-49F7-B186-9F65903C4CC1Q34311881-02F9966A-DE35-47C8-9A34-E5B2589B0DE5Q34611568-CB57F531-187D-4BC6-92DD-027AA2E9730AQ34720254-1AA39ED5-389B-4AC9-9BAC-DBE9F598DE2FQ34854883-C6D27A9D-E3FC-43B1-931F-5BD0C550DEC2Q35124596-AABD5204-4229-4B51-8F90-637FD05823E2Q35410361-F431050D-1D28-4B5A-89F5-DBB7C11DE8CFQ35579053-6BA7B0F9-E319-46C8-BC8B-7C4315345926Q35737352-7018D89F-F840-418B-859C-43467A01CE18Q35804614-8D97BEFF-AF17-4E78-B8CB-451D4EDC2E9BQ36210460-936D62A6-754B-465C-B519-FA949BD9A6D6Q37661498-76517DC2-81C2-4AB9-AE61-6719A7A06C9EQ37678826-3D457FBC-D9F0-4A83-B474-499ECEC886CAQ37728699-DCE555A2-8360-461B-B38A-221B7AB4BFB4Q38126995-7C8344CA-1AB0-44F5-AF9F-F2D22F0F6432Q39223582-A98984F8-B453-44B4-A82E-3C2E024B1362Q41342922-B5B704FE-2EE0-4EEE-8E2F-C92397A4EFADQ42458495-11596EFE-2A17-4C8A-87BE-DB5873DAB664Q44118153-2D7C27DC-A995-4753-A746-881245D8B9A2Q47852784-7A5EC504-B2AE-46F9-B221-2E8EE3129084
P50
description
onderzoeker
@nl
name
Hans Kristian Moen Vollan
@ast
Hans Kristian Moen Vollan
@en
Hans Kristian Moen Vollan
@es
Hans Kristian Moen Vollan
@sl
type
label
Hans Kristian Moen Vollan
@ast
Hans Kristian Moen Vollan
@en
Hans Kristian Moen Vollan
@es
Hans Kristian Moen Vollan
@sl
prefLabel
Hans Kristian Moen Vollan
@ast
Hans Kristian Moen Vollan
@en
Hans Kristian Moen Vollan
@es
Hans Kristian Moen Vollan
@sl